第3至5天的泊沙康唑血药浓度可预测稳态水平。
Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels.
作者信息
Prattes Jürgen, Duettmann Wiebke, Hoenigl Martin
机构信息
Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Graz, Austria Center for Biomarker Research in Medicine, Graz, Austria.
Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Graz, Austria Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
出版信息
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5595-9. doi: 10.1128/AAC.00389-16. Print 2016 Sep.
Abstract
Low posaconazole plasma concentrations (PPCs) have been associated with breakthrough invasive fungal infections. We assessed the correlation between pre-steady-state PPCs (obtained between days 3 and 5) and PPCs obtained during steady state in 48 patients with underlying hematological malignancies receiving posaconazole oral-solution prophylaxis. Pre-steady-state PPCs correlated significantly with PPCs obtained at steady state (Spearman r = 0.754; P < 0.001). Receiver operating characteristic (ROC) curve analysis of pre-steady-state PPCs revealed an area under the curve (AUC) of 0.884 (95% confidence interval [CI], 0.790 to 0.977) for predicting satisfactory PPCs at steady state.
摘要
泊沙康唑血浆浓度（PPCs）较低与侵袭性真菌感染的突破性发作有关。我们评估了48例接受泊沙康唑口服溶液预防的血液系统恶性肿瘤患者在达到稳态前（第3至5天）的PPCs与稳态时获得的PPCs之间的相关性。达到稳态前的PPCs与稳态时获得的PPCs显著相关（斯皮尔曼r = 0.754；P < 0.001）。对达到稳态前的PPCs进行的受试者工作特征（ROC）曲线分析显示，预测稳态时PPCs达到满意水平的曲线下面积（AUC）为0.884（95%置信区间[CI]，0.790至0.977）。
相似文献
1
Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels.
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5595-9. doi: 10.1128/AAC.00389-16. Print 2016 Sep.
2
Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies.
Int J Antimicrob Agents. 2012 Jun;39(6):510-3. doi: 10.1016/j.ijantimicag.2012.02.002. Epub 2012 Apr 3.
3
Impact of structured personal on-site patient education on low posaconazole plasma concentrations in patients with haematological malignancies.
Int J Antimicrob Agents. 2014 Aug;44(2):140-4. doi: 10.1016/j.ijantimicag.2014.03.013. Epub 2014 May 21.
4
Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients.
Eur J Clin Pharmacol. 2016 Aug;72(8):953-63. doi: 10.1007/s00228-016-2057-6. Epub 2016 Apr 11.
5
Antifungal Prophylaxis with Posaconazole Delayed-Release Tablet and Oral Suspension in a Real-Life Setting: Plasma Levels, Efficacy, and Tolerability.
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.02655-17. Print 2018 Jun.
6
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
Antimicrob Agents Chemother. 2007 Mar;51(3):812-8. doi: 10.1128/AAC.00454-06. Epub 2007 Jan 8.
7
Posaconazole serum level on day 2 predicts steady state posaconazole serum level.
Ther Drug Monit. 2012 Feb;34(1):118-9. doi: 10.1097/FTD.0b013e31823cef77.
8
Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with haematologic malignancy: Therapeutic drug monitoring, efficacy and risk factors for the suboptimal level.
Mycoses. 2020 Jan;63(1):89-94. doi: 10.1111/myc.13020. Epub 2019 Nov 20.
9
Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.
Antimicrob Agents Chemother. 2015 Aug;59(8):4424-8. doi: 10.1128/AAC.00581-15. Epub 2015 May 18.
10
Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults.
Antimicrob Agents Chemother. 2009 Dec;53(12):5224-9. doi: 10.1128/AAC.00939-09. Epub 2009 Sep 14.
引用本文的文献
1
Approaches for posaconazole therapeutic drug monitoring and their clinical benefits.
Eur J Clin Pharmacol. 2024 Dec;80(12):1845-1855. doi: 10.1007/s00228-024-03756-9. Epub 2024 Sep 9.
2
Real-world Experience of Posaconazole Therapeutic Drug Monitoring in Oncology Patients: Clinical Implications of Hypoalbuminemia as a Predictor of Subtherapeutic Posaconazole Levels.
Open Forum Infect Dis. 2024 Mar 29;11(5):ofae185. doi: 10.1093/ofid/ofae185. eCollection 2024 May.
3
Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
J Antimicrob Chemother. 2023 Aug 2;78(8):1813-1826. doi: 10.1093/jac/dkad143.
4
Treatment of Invasive Aspergillosis: How It's Going, Where It's Heading.
Mycopathologia. 2023 Oct;188(5):667-681. doi: 10.1007/s11046-023-00727-z. Epub 2023 Apr 26.
5
Salvage Treatment for Invasive Aspergillosis and Mucormycosis: Challenges, Recommendations and Future Considerations.
Infect Drug Resist. 2023 Apr 12;16:2167-2178. doi: 10.2147/IDR.S372546. eCollection 2023.
6
Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.
Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0215621. doi: 10.1128/aac.02156-21. Epub 2022 Jun 29.
7
Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study.
Crit Care. 2021 Sep 15;25(1):335. doi: 10.1186/s13054-021-03753-9.
8
and aspergillosis: From basics to clinics.
Stud Mycol. 2021 May 10;100:100115. doi: 10.1016/j.simyco.2021.100115. eCollection 2021 Sep.
9
Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology.
Mycoses. 2019 Sep;62(9):716-729. doi: 10.1111/myc.12960. Epub 2019 Jul 19.
10
Treatment of Aspergillosis.
J Fungi (Basel). 2018 Aug 19;4(3):98. doi: 10.3390/jof4030098.
本文引用的文献
1
Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections.
Mycoses. 2016 Apr;59(4):226-233. doi: 10.1111/myc.12452. Epub 2016 Jan 6.
2
Visual Hallucinations Associated with High Posaconazole Concentrations in Serum.
Antimicrob Agents Chemother. 2015 Dec 7;60(2):1170-1. doi: 10.1128/AAC.02739-15. Print 2016 Feb.
3
Subtherapeutic Posaconazole Exposure and Treatment Outcome in Patients With Invasive Fungal Disease.
Ther Drug Monit. 2015 Dec;37(6):766-71. doi: 10.1097/FTD.0000000000000235.
4
Pharmacokinetics of Posaconazole Oral Suspension in Children Dosed According to Body Surface Area.
Pediatr Infect Dis J. 2016 Feb;35(2):183-8. doi: 10.1097/INF.0000000000000963.
5
Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis.
Mycoses. 2015 Jul;58(7):432-6. doi: 10.1111/myc.12339. Epub 2015 Jun 23.
6
Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension.
Antimicrob Agents Chemother. 2015 Aug;59(8):4914-8. doi: 10.1128/AAC.00496-15. Epub 2015 Jun 8.
7
Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.
Antimicrob Agents Chemother. 2015 Aug;59(8):4424-8. doi: 10.1128/AAC.00581-15. Epub 2015 May 18.
8
Impact of structured personal on-site patient education on low posaconazole plasma concentrations in patients with haematological malignancies.
Int J Antimicrob Agents. 2014 Aug;44(2):140-4. doi: 10.1016/j.ijantimicag.2014.03.013. Epub 2014 May 21.
9
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.
J Antimicrob Chemother. 2014 May;69(5):1162-76. doi: 10.1093/jac/dkt508. Epub 2013 Dec 29.
10
Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis.
J Infect Dis. 2013 Nov 15;208(10):1717-28. doi: 10.1093/infdis/jit358. Epub 2013 Aug 1.
Zotero 插件